Goldman Sachs Group Inc Adicet Bio, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 3,759,997 shares of ACET stock, worth $3.35 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,759,997
Previous 4,283,372
12.22%
Holding current value
$3.35 Million
Previous $5.18 Million
4.48%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ACET
# of Institutions
72Shares Held
59.2MCall Options Held
4.2KPut Options Held
6.7K-
Orbimed Advisors LLC San Diego, CA11.4MShares$10.2 Million0.39% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$7.31 Million1.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$6.71 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.21MShares$2.85 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC2.95MShares$2.62 Million0.64% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $35.6M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...